[go: up one dir, main page]

MX2016012120A - Anticuerpos de il-21. - Google Patents

Anticuerpos de il-21.

Info

Publication number
MX2016012120A
MX2016012120A MX2016012120A MX2016012120A MX2016012120A MX 2016012120 A MX2016012120 A MX 2016012120A MX 2016012120 A MX2016012120 A MX 2016012120A MX 2016012120 A MX2016012120 A MX 2016012120A MX 2016012120 A MX2016012120 A MX 2016012120A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
compositions
conditions
warranted
Prior art date
Application number
MX2016012120A
Other languages
English (en)
Inventor
Davies Julian
Magrini Fabio
Paula Martin Andrea
Mozaffarian Neelufar
Natvarlal PATEL Chetankumar
Schroeder Oliver
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016012120A publication Critical patent/MX2016012120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados, diseñados por ingeniería que tienen alta afinidad para y neutralizan a lL-21 humana, métodos para usar los anticuerpos para tratar condiciones en las cuales el antagonismo o neutralización de los efectos de lL-21 está garantizado, tales como condiciones autoinmunes, composiciones y métodos para producir recombinantemente los anticuerpos, y composiciones farmacéuticas que comprenden los anticuerpos.
MX2016012120A 2014-03-21 2015-03-13 Anticuerpos de il-21. MX2016012120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (en) 2014-03-21 2015-03-13 Il-21 antibodies

Publications (1)

Publication Number Publication Date
MX2016012120A true MX2016012120A (es) 2016-12-09

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012120A MX2016012120A (es) 2014-03-21 2015-03-13 Anticuerpos de il-21.

Country Status (24)

Country Link
US (1) US9394362B2 (es)
EP (1) EP3119806B1 (es)
JP (2) JP6053989B2 (es)
KR (1) KR101859857B1 (es)
CN (1) CN106061999B (es)
AP (1) AP2016009450A0 (es)
AR (1) AR099625A1 (es)
AU (1) AU2015231777B2 (es)
BR (1) BR112016019176A2 (es)
CA (1) CA2939543C (es)
CL (1) CL2016002281A1 (es)
EA (1) EA033335B1 (es)
EC (1) ECSP16075416A (es)
ES (1) ES2774422T3 (es)
IL (1) IL246909A0 (es)
MA (1) MA39342B2 (es)
MX (1) MX2016012120A (es)
MY (1) MY177915A (es)
NZ (1) NZ722518A (es)
PE (1) PE20161221A1 (es)
PH (1) PH12016501820A1 (es)
SG (1) SG11201606705QA (es)
TW (1) TWI646105B (es)
WO (1) WO2015142637A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3128997B1 (en) 2014-04-08 2020-08-05 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
JP2018536650A (ja) * 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017172509A1 (en) * 2016-03-31 2017-10-05 Eli Lilly And Company Il-21 antibodies and uses thereof
BR112020022892A2 (pt) * 2018-05-31 2021-02-23 Glycom A/S mistura de hmos para tratamento de doenças autoi-munes
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
KR20240035825A (ko) 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525611A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
KR20240035824A (ko) * 2021-07-09 2024-03-18 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275221B (zh) * 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
KR20050119120A (ko) 2003-03-14 2005-12-20 와이어쓰 인간 ⅰｌ-21 수용체에 대한 항체 및 그것의 용도
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
EP2567973B1 (en) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
US7592427B2 (en) * 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
BRPI0820099A2 (pt) * 2007-12-07 2020-11-24 Zymogenetics, Inc anticorpo isolado ou fragmento de anticorpo, composição farmacêutica, e, uso de um anticorpo ou fragmento de anticorpo
CN102027011B (zh) * 2007-12-07 2014-09-03 津莫吉尼蒂克斯公司 抗人il-21单克隆抗体
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
EP2714198A1 (en) * 2011-05-31 2014-04-09 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
EA033335B1 (ru) 2019-09-30
JP6053989B2 (ja) 2017-01-11
NZ722518A (en) 2017-12-22
JP6373944B2 (ja) 2018-08-15
AU2015231777A1 (en) 2016-08-18
US20150266954A1 (en) 2015-09-24
TW201623330A (zh) 2016-07-01
CN106061999B (zh) 2020-07-31
IL246909A0 (en) 2016-09-29
MY177915A (en) 2020-09-25
AP2016009450A0 (en) 2016-09-30
MA39342A1 (fr) 2018-03-30
BR112016019176A2 (pt) 2017-10-10
CL2016002281A1 (es) 2017-06-23
EP3119806A1 (en) 2017-01-25
AU2015231777B2 (en) 2017-08-03
EA201691521A1 (ru) 2017-02-28
KR101859857B1 (ko) 2018-05-18
AR099625A1 (es) 2016-08-03
ES2774422T3 (es) 2020-07-21
KR20160124166A (ko) 2016-10-26
US9394362B2 (en) 2016-07-19
ECSP16075416A (es) 2018-05-31
CA2939543A1 (en) 2015-09-24
MA39342B2 (fr) 2020-03-31
TWI646105B (zh) 2019-01-01
PE20161221A1 (es) 2016-11-12
JP2016520088A (ja) 2016-07-11
JP2017093435A (ja) 2017-06-01
CA2939543C (en) 2018-01-16
WO2015142637A1 (en) 2015-09-24
CN106061999A (zh) 2016-10-26
PH12016501820A1 (en) 2016-11-07
SG11201606705QA (en) 2016-09-29
EP3119806B1 (en) 2020-01-01
EP3119806A4 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
PH12016501820A1 (en) Il-21 antibodies
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12018500684A1 (en) Agonistic antibodies specifically binding human cd40 and methods of use
MX2021014956A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
JO3798B1 (ar) الأجسام المضادة ملزمة على وجه التحديد pd-1 واستخداماتها
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12017501522A1 (en) Antibodies to tau and uses thereof
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
NZ738480A (en) Factor xi antibodies and methods of use
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12016502535B1 (en) Interferon alpha and omega antibody antagonists
PH12018500203A1 (en) Anti-cd154 antibodies and methods of using them
TN2018000289A1 (en) Antibodies for il-17c
PH12018500445B1 (en) Use of anti-cd40 antibodies for treatment of lupus nephritis
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use